19 results about "Pulmonary embolism" patented technology

The invention relates to the technical field of image processing, and discloses a pulmonary embolism focus segmentation method and system based on image recognition, and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain embolism characteristic parameters; the pixel embolism probability is estimated through variational Bayesian reasoning, and a focus distribution diagram is generated; performing multi-scale feature fusion on the lesion probability graph to obtain a segmentation boundary; and obtaining a final embolism focus segmentation result based on the vascular connectivity constraint optimization boundary. The problems that blood vessel level differentiation processing cannot be achieved, and accurate probability modeling and anatomical constraint verification are lacked are solved. The accuracy of pulmonary embolism focus segmentation is improved.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The application discloses a method for constructing a 4D FLOW-based hemodynamic evaluation pulmonary embolism prognosis prediction model and application, relates to the medical image technology field, and comprises the following steps: collecting 4D-Flow images of patients who have been diagnosed with pulmonary embolism from medical institutions to obtain image data A; pre-processing the image data A, and dividing the pre-processed image data A into a training set and a verification set according to a proportion; respectively performing imageomic feature extraction, clinical feature extraction and 4D FLOW hemodynamic feature extraction on the training set and the verification set; screening the imageomic features and the clinical features and 4D FLOW hemodynamic detection indexes to obtain key features; and based on the key features, establishing a multi-omics prediction model for pulmonary embolism prognosis prediction, thereby providing a new imaging reference for pulmonary embolism treatment.

Methods for performing non-invasive thrombolysis with ultrasound using, in some embodiments, one or more ultrasound transducers to focus or place a high intensity ultrasound beam onto a blood clot (thrombus) or other vascular inclusion or occlusion (e.g., clot in the dialysis graft, deep vein thrombosis, superficial vein thrombosis, arterial embolus, bypass graft thrombosis or embolization, pulmonary embolus) which would be ablated (eroded, mechanically fractionated, liquefied, or dissolved) by ultrasound energy. The process can employ one or more mechanisms, such as of cavitational, sonochemical, mechanical fractionation, or thermal processes depending on the acoustic parameters selected. This general process, including the examples of application set forth herein, is henceforth referred to as “Thrombolysis.”

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application provides a filter for breaking up thrombus. The filter comprises a power conversion mechanism, a filter support and a cutting mechanism which are connected in sequence along an axial direction and can be radially expanded and contracted; the power conversion mechanism and the cutting mechanism are axially limited and can rotate circumferentially relative to the filter support; the power conversion mechanism can convert the power of blood flow flowing from the cutting mechanism to the power conversion mechanism into rotary motion and can drive the cutting mechanism to rotate circumferentially in the filter support. According to the embodiment of the application, the cutting mechanism is driven by the power conversion mechanism to rotate circumferentially in the filter support, so that the thrombus intercepted in the filter support can be continuously cut and broken up, thereby avoiding pulmonary embolism and preventing blood vessel embolism caused by the filter for breaking up thrombus.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

Embodiments of the present specification provide a method for determining a pulmonary embolism index. The method comprises: obtaining a medical image of a subject, the medical image comprising pulmonary blood vessels of the subject, the pulmonary blood vessels of the subject comprising a thrombus; determining information related to the thrombus based on the medical image; dividing the pulmonary blood vessels into at least two hierarchical blood vessels based on the medical image; and determining a pulmonary embolism index of the subject based on the information related to the thrombus and the at least two hierarchical blood vessels.

The utility model discloses a novel device for preventing lower limb venous thrombosis of a bedridden patient, which comprises a rack assembly, a vibration assembly, a surrounding movement assembly and an inflation assembly, the vibration assembly, the surrounding movement assembly and the inflation assembly are all arranged in the rack assembly, the surrounding movement assembly is arranged above the inflation assembly, and the inflation assembly is arranged above the surrounding movement assembly. A vibration assembly is installed behind the surrounding movement assembly, the lower limbs of a patient are placed in the inflatable foot sleeve, the inflatable foot sleeve conducts intermittent pneumatic repeated compression movement on the lower limbs of the patient through an air pump, the venous blood flow speed of the patient is increased, blood agglutination is prevented, and deep venous thrombosis and pulmonary embolism are prevented. After the patient wears the inflation assembly on the leg, the leg is placed in a positioning soft groove in the surrounding assembly or placed above the vibration assembly, the surrounding movement assembly conducts clockwise rotation movement and anticlockwise rotation movement to simulate back stretching, toe flexion and surrounding movement of the ankle joint of the human body so as to prevent thrombus, and the vibration assembly is used for promoting blood circulation. And thrombus is prevented.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application relates to the technical field of image processing, and discloses a pulmonary embolism lesion segmentation method and system based on image recognition and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain an embolism characteristic parameter; estimating a pixel embolism probability by using variational Bayesian inference to generate a lesion distribution map; performing multi-scale feature fusion on the lesion probability map to obtain a segmentation boundary; and optimizing the boundary based on blood vessel connectivity constraints to obtain a final embolism lesion segmentation result. The application solves the problems that blood vessel level differentiation processing cannot be realized, accurate probability modeling is lacked, and anatomic constraint verification is lacked. The application improves the precision of pulmonary embolism lesion segmentation.

The invention discloses a device capable of continuously monitoring and preventing lower limb venous thrombosis and a control method thereof, the device comprises a signal acquisition device, a controller and a host, the signal acquisition device can continuously monitor target venous blood flow dynamics and muscle electric signal changes of human lower limbs, and can electrically stimulate lower limb muscles; the controller can transmit a control instruction sent by the host to the signal acquisition device, and can convert an ultrasonic analog signal and a myoelectricity analog signal into a high-quality ultrasonic image and a specific numerical value of an action potential; the host can send a control instruction to the controller, calculate the blood flow speed and the inner diameter value of a target vein according to the ultrasonic digital signal processed by the controller, monitor and display the blood flow speed and the inner diameter value of the target vein together with the high-quality ultrasonic image and the specific numerical value of the action potential, and select a corresponding electrical stimulation scheme. According to the invention, real-time monitoring and individualized precise prevention of lower limb venous hemodynamics are realized, and powerful support is provided for reducing the incidence rate of clinical lower limb venous thrombosis and pulmonary embolism.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

The invention discloses a fixed transfer pad, and relates to the field of medical instruments. A fixed transfer pad comprises a medical transfer pad, a plurality of hand lifting holes are formed in the two sides of the medical transfer pad at equal intervals, the fixed transfer pad further comprises a lifting air bag pad fixedly installed on one side of the medical transfer pad, an inflation inlet is formed in one side of the lifting air bag pad, and the included angle between the inclined plane of the upper side of the lifting air bag pad and the medical transfer pad is 30 degrees; movement of an affected limb can be reduced to the maximum extent, the risk that thrombus falls off and causes pulmonary embolism is reduced, the design that the affected limb is lifted by 30 degrees by lifting the air bag cushion is adopted, and the slope position is beneficial to promoting blood backflow of the affected limb and reducing blood stasis on the lower limb, so that thrombus is prevented from being further aggravated, and favorable conditions are created for rehabilitation of a patient; meanwhile, the scientific lifting mode can relieve edema of the lower limbs, relieve pain and discomfort of the patient and play a positive role in promoting recovery of the illness state of the patient.

The application discloses a kind of for thoracolumbar fracture front and rear road's minimally invasive bone cement device and use method, and the application belongs to medical equipment technical field, comprising: puncture guiding mechanism, bone cement mechanism, including passage dilator, the passage dilator is detachably installed with the sheet mechanism in, the bottom of sheet body is arc structure;Bone cement injection mechanism.The application solves the risk of bone cement leakage by setting bone cement bag, and then reduces the risk of bone cement leakage to the spinal canal or paravertebral tissue, so as to avoid nerve damage, pulmonary embolism and other serious complications.The specific shape can be formed in the fractured vertebral body by the setting of the sheet mechanism, the uniform distribution of bone cement in the vertebral body is ensured by introducing bone cement distribution control mechanism, the stability of fractured vertebral body is enhanced, and the treatment effect is improved.Meanwhile, the effective recovery of the height of severely compressed fractured vertebral body is realized, and the postoperative physiological curvature and function of the patient's spine are improved.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.